ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:PRQR
- CUSIP: N/A
- Web: www.proqr.com
Capitalization:- Market Cap: $119.06 million
- Outstanding Shares: 24,105,000
Average Prices:- 50 Day Moving Avg: $5.11
- 200 Day Moving Avg: $4.81
- 52 Week Range: $3.65 - $8.70
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.49
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $1.19 million
- Price / Sales: 96.22
- Book Value: $1.79 per share
- Price / Book: 2.65
Profitability:- EBIDTA: ($46,110,000.00)
- Return on Equity: -82.16%
- Return on Assets: -66.16%
Debt:- Debt-to-Equity Ratio: 0.17%
- Current Ratio: 8.22%
- Quick Ratio: 8.22%
Misc:- Average Volume: 14,175 shs.
- Beta: 0.86
- Short Ratio: 5.21
Frequently Asked Questions for ProQR Therapeutics N.V. (NASDAQ:PRQR)
What is ProQR Therapeutics N.V.'s stock symbol?
ProQR Therapeutics N.V. trades on the NASDAQ under the ticker symbol "PRQR."
How were ProQR Therapeutics N.V.'s earnings last quarter?
ProQR Therapeutics N.V. (NASDAQ:PRQR) announced its quarterly earnings results on Wednesday, May, 17th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.02. View ProQR Therapeutics N.V.'s Earnings History.
When will ProQR Therapeutics N.V. make its next earnings announcement?
Where is ProQR Therapeutics N.V.'s stock going? Where will ProQR Therapeutics N.V.'s stock price be in 2017?
5 analysts have issued twelve-month target prices for ProQR Therapeutics N.V.'s stock. Their forecasts range from $4.50 to $40.00. On average, they expect ProQR Therapeutics N.V.'s share price to reach $16.38 in the next twelve months. View Analyst Ratings for ProQR Therapeutics N.V..
What are analysts saying about ProQR Therapeutics N.V. stock?
Here are some recent quotes from research analysts about ProQR Therapeutics N.V. stock:
- 1. HC Wainwright analysts commented, "Emile Yu – (212-916-3972) / [email protected]/* */ Takeaways From the R&D Day We see multipronged value going forward after last week’s R&D Day. We believe that in the last three years since its IPO, ProQr has executed successfully on a transformation from a one-oligo CF company to an RNA- platform pipeline with multiple orphan/pediatric indications on deck. In doing so, the company has elected to make RNA technology its core competency, and is now doubling down by leveraging this core competency to hit multiple orphan targets. Meanwhile, as we look at the development and clinical plan, we applaud the array of indications that appears designed to minimize risk in formulation and delivery, and shorten development/regulatory time. According to management, the current goal is to have three clinical programs with data by end-2018. In our view, this looks achievable, with Phase 1b CF data on tap for this Sept, the IND for the Phase 1 LCA study now open, and a study in EB planned for 2018. Of note, we highlight that the rising programs in ophtho and derm may allow for a short trial and regulatory timetable, potentially even beating the CF program on a race to commercial value, all else equal." (6/20/2017)
- 2. According to Zacks Investment Research, "ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. " (5/3/2017)
Who are some of ProQR Therapeutics N.V.'s key competitors?
Some companies that are related to ProQR Therapeutics N.V. include Catalyst Pharmaceuticals (CPRX), ObsEva SA (OBSV), Tocagen (TOCA), Urogen Pharma (URGN), Ardelyx (ARDX), Pieris Pharmaceuticals (PIRS), uniQure N.V. (QURE), Chimerix (CMRX), Immune Design Corp. (IMDZ), Madrigal Pharmaceuticals (MDGL), Kindred Biosciences (KIN), Athersys (ATHX), Stemline Therapeutics (STML), Faron Pharmaceuticals Oy (FARN), Cascadian Therapeutics (CASC), Zymeworks (ZYME), AILERON THERAP (ALRN) and Clearside Biomedical (CLSD).
Who are ProQR Therapeutics N.V.'s key executives?
ProQR Therapeutics N.V.'s management team includes the folowing people:
- Daniel De Boer, Founding Chief Executive Officer
- Gerard Platenburg, Co-Founder, Chief Innovation Officer
- Smital Shah, Chief Financial Officer
- Rene K. Beukema, Chief Corporate Development Officer and General Counsel
- Noreen Henig, Chief Development Officer
Who owns ProQR Therapeutics N.V. stock?
ProQR Therapeutics N.V.'s stock is owned by many different of retail and institutional investors. Top institutional investors include Jennison Associates LLC (10.36%), Redmile Group LLC (6.69%),
INVUS PUBLIC EQUITIES, L.P.
(6.00%), Artal Group S.A. (2.10%), Janus Henderson Group PLC (1.63%) and Sphera Funds Management LTD. (1.38%). View Institutional Ownership Trends for ProQR Therapeutics N.V..
Who sold ProQR Therapeutics N.V. stock? Who is selling ProQR Therapeutics N.V. stock?
Who bought ProQR Therapeutics N.V. stock? Who is buying ProQR Therapeutics N.V. stock?
How do I buy ProQR Therapeutics N.V. stock?
Shares of ProQR Therapeutics N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ProQR Therapeutics N.V.'s stock price today?
One share of ProQR Therapeutics N.V. stock can currently be purchased for approximately $4.75.
MarketBeat Community Rating for ProQR Therapeutics N.V. (NASDAQ PRQR)MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ProQR Therapeutics N.V. (NASDAQ:PRQR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $16.38 (244.74% upside) |
Analysts' Ratings History for ProQR Therapeutics N.V. (NASDAQ:PRQR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/20/2017 | HC Wainwright | Reiterated Rating | Buy | $40.00 | High |  |
| 10/31/2016 | Chardan Capital | Reiterated Rating | Hold | $4.50 | N/A | |
| 10/14/2016 | Leerink Swann | Reiterated Rating | Outperform | $14.00 | N/A | |
| 9/28/2016 | Janney Montgomery Scott | Initiated Coverage | Neutral | $7.00 | N/A | |
| 9/6/2016 | JMP Securities | Reiterated Rating | Buy | | N/A | |
(Data available from 8/22/2015 forward)
Earnings History for ProQR Therapeutics N.V. (NASDAQ:PRQR)Earnings History by Quarter for ProQR Therapeutics N.V. (NASDAQ PRQR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | ($0.52) | | | | | N/A | |
| 5/17/2017 | 3/31/2017 | ($0.50) | ($0.48) | $0.32 million | | View | N/A | |
| 5/18/2016 | Q1 | ($0.41) | ($0.50) | $0.22 million | | View | N/A | |
| 2/17/2016 | Q4 | ($0.35) | ($0.29) | | | View | N/A | |
| 11/23/2015 | Q3 | ($0.36) | ($0.29) | | | View | N/A | |
| 8/19/2015 | | ($0.32) | ($0.41) | | | View | N/A | |
| 5/21/2015 | | ($0.29) | $0.01 | | | View | N/A | |
| 2/26/2015 | | ($0.27) | ($0.30) | | | View | N/A | |
| 11/24/2014 | | ($1.00) | ($0.53) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ProQR Therapeutics N.V. (NASDAQ:PRQR)2017 EPS Consensus Estimate: ($2.00)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.49) | ($0.49) | ($0.49) |
| Q2 2017 | 1 | ($0.51) | ($0.51) | ($0.51) |
| Q3 2017 | 1 | ($0.49) | ($0.49) | ($0.49) |
| Q4 2017 | 1 | ($0.51) | ($0.51) | ($0.51) |
(Data provided by Zacks Investment Research)
Dividend History for ProQR Therapeutics N.V. (NASDAQ:PRQR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ProQR Therapeutics N.V. (NASDAQ:PRQR)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for ProQR Therapeutics N.V. (NASDAQ:PRQR)
Latest Headlines for ProQR Therapeutics N.V. (NASDAQ:PRQR)
| Source: |
|
| Date | Headline |
|---|
 | Brokers Offer Predictions for ProQR Therapeutics N.V.'s Q3 2017 Earnings (PRQR)
www.americanbankingnews.com - August 18 at 6:26 AM |
 | ProQR Announces Results for the Second Quarter of 2017
globenewswire.com - August 17 at 7:04 AM |
| ProQR Therapeutics N.V. (PRQR) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 15 at 11:56 AM |
| ProQR Therapeutics N.V. (NASDAQ:PRQR) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - August 8 at 7:08 AM |
| ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 9:10 AM |
 | ProQR's Usher Syndrome Candidate Gets Orphan Drug Status
finance.yahoo.com - July 7 at 8:17 AM |
 | ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
www.nasdaq.com - July 5 at 9:44 AM |
 | ProQR (PRQR) Investigational Drug QRX-411 for Usher Syndrome Granted Orphan Drug Designation from FDA & EMA
www.streetinsider.com - July 5 at 9:44 AM |
| ProQR's Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
finance.yahoo.com - July 5 at 9:44 AM |
| ProQR Therapeutics N.V. (PRQR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 26 at 8:54 AM |
| ProQR Therapeutics N.V. (PRQR) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - June 20 at 7:58 AM |
 | ProQR presents R&D day highlights progress and introduces Axiomer, a novel proprietary RNA technology
seekingalpha.com - June 16 at 9:04 AM |
| ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology
finance.yahoo.com - June 16 at 9:04 AM |
 | ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference
feeds.benzinga.com - June 13 at 7:23 AM |
| ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
finance.yahoo.com - June 8 at 8:13 PM |
| ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
finance.yahoo.com - May 31 at 1:02 PM |
| ProQR Therapeutics NV (PRQR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 7:58 AM |
| ProQR Therapeutics NV (PRQR) Short Interest Up 2.2% in April
www.americanbankingnews.com - May 22 at 4:14 PM |
| Brokers Issue Forecasts for ProQR Therapeutics NV's Q3 2017 Earnings (PRQR)
www.americanbankingnews.com - May 19 at 7:28 AM |
| ProQR Therapeutics NV (PRQR) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 18 at 10:44 AM |
| ProQR Announces Results for the First Quarter of 2017
finance.yahoo.com - May 17 at 7:15 PM |
| ProQR remembers co-founder Henri Termeer after his unexpected passing
finance.yahoo.com - May 15 at 9:48 AM |
| ProQR Announces R&D Day in New York on June 15
finance.yahoo.com - May 9 at 11:00 AM |
| ProQR Therapeutics NV (PRQR) Earning Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - May 4 at 10:37 AM |
| ProQR Therapeutics NV (PRQR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 3 at 10:03 AM |
| ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
finance.yahoo.com - May 1 at 11:11 AM |
| ProQR Therapeutics NV (PRQR) Earning Somewhat Critical News Coverage, Study Shows
www.americanbankingnews.com - April 28 at 3:54 PM |
| ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
finance.yahoo.com - April 27 at 10:36 AM |
| ProQR Therapeutics NV (PRQR) Receives Media Sentiment Rating of -0.16
www.americanbankingnews.com - April 22 at 7:32 AM |
| ProQR to Present at the Deutsche Bank Health Care Conference
finance.yahoo.com - April 20 at 8:48 AM |
| ProQR Therapeutics NV (PRQR) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 19 at 7:29 AM |
| ProQR Therapeutics NV (PRQR) Receives Media Sentiment Score of 0.31
www.americanbankingnews.com - April 13 at 7:46 PM |
| ProQR Announces Annual Meeting of Shareholders
finance.yahoo.com - April 10 at 9:38 AM |
| ProQR Therapeutics NV (PRQR) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 7 at 9:05 PM |
 | 7:05 am ProQR Therapeutics announces the grant of two key patents protecting QR-010 in the US and EU, these patents provide the Co exclusive rights for QR-010 for the treatment of cystic fibrosis until at least July 2033
us.rd.yahoo.com - April 3 at 11:47 PM |
| ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
finance.yahoo.com - March 27 at 9:38 AM |
| ProQR Therapeutics NV (PRQR) Downgraded by Zacks Investment Research to “Hold”
www.americanbankingnews.com - March 13 at 2:48 PM |
| ProQR to Present at Two Upcoming Investor Conferences in March
finance.yahoo.com - March 1 at 7:36 PM |
| ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
us.rd.yahoo.com - February 28 at 3:49 PM |
| On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
finance.yahoo.com - February 27 at 9:44 AM |
| Can The Uptrend Continue for ProQR Therapeutics (PRQR)?
finance.yahoo.com - December 29 at 8:58 AM |
| Blog Coverage ProQR Cystic Fibrosis Drug Meets Primary End Point
finance.yahoo.com - October 28 at 10:41 AM |
| Mid-Morning Market Update: Markets Open Higher; Twitter Beats Q3 Expectations
www.nasdaq.com - October 27 at 11:52 AM |
| ProQR Therapeutics (PRQR) Worth a Look: Stock Up 9.8%
finance.yahoo.com - October 27 at 11:52 AM |
 | ProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test
www.thestreet.com - October 27 at 11:52 AM |
| ProQR Jumps on Positive Phase 1 Results
finance.yahoo.com - October 27 at 11:52 AM |
| ProQR Therapeutics N.V. (PRQR) is Overbought: Is A Drop Coming?
finance.yahoo.com - September 27 at 6:45 PM |
| ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis
finance.yahoo.com - July 19 at 7:00 AM |
| Coverage initiated on ProQR Therapeutics by Chardan Capital Markets
finance.yahoo.com - June 20 at 5:50 AM |
| 7:04 am ProQR Therapeutics confirms that its investigational drug QR-110 has received orphan drug designation from both the FDA and the EMA for the treatment of Leber's congenital amaurosis Type 10
finance.yahoo.com - June 1 at 7:04 AM |
ProQR Therapeutics N.V. (PRQR) Chart for Tuesday, August, 22, 2017
